PR88746

LONDON and BELGRADE, Serbia, April 1, 2021 /PRNewswire=KYODO JBN/ --

-  Zdravlje is a leading pharmaceutical manufacturer which supplies more than

35 countries around the world  

-  The Company has a 65+ year track record in supplying high quality

pharmaceutical products across oral solid and liquid forms

-  Zdravlje represents a solid foundation upon which a leading international

pharmaceutical platform will be built over the coming years

Frontier Pharma [ http://www.frontierpharma.co.uk/ ]and Baystone Group today

announced the completion of its acquisition of Zdravlje A.D

[http://www.zdravlje.co.rs/ ]from Teva Pharmaceuticals. Zdravlje currently

supplies high quality pharmaceuticals to more than 35 international markets

including those in Western & Eastern Europe, U.K., Asia-Pacific, Sub-Saharan

Africa and Latin America.  

"We are incredibly pleased to complete this transaction and support Zdravlje as

a leading independent pharmaceutical company. We look forward to working

together with the exceptionally talented team at Zdravlje to further develop

the Company into a leading international pharmaceutical company." said M.

Levent Selamoglu, Chairman of Frontier Pharma.

Established in 1953, Zdravlje has a 67 year track record in the manufacture and

supply of high quality pharmaceutical products. The Company currently employs

more than 250 people and manufactures a large portfolio of oral solid and

liquid products to treat a range of serious and chronic diseases including

cardiovascular, central nervous system and respiratory disorders, amongst

others. Zdravlje also brings a portfolio of complementary branded generic

pharmaceutical products which forms the foundation of an independent commercial

strategy under the "Zdravlje" brand.

"We look forward to leveraging Zdravlje's extensive track record as a premium

global supplier to create an industry-leading, fully integrated pharma

platform." said Kiren Naidoo, CEO of Frontier Pharma.

"This is a key milestone in Zdravlje's history and we are delighted to continue

our successful business in the pharmaceutical industry by providing our high

quality products to more than 35 countries around the world and to support the

local community in which we have successfully operated in for more than 67

years" said Bojan Jovic, Zdravlje's General Manager.

About Frontier Pharma and Baystone Group

Frontier Pharma is a U.K.-based specialist pharmaceutical investor and operator

founded by M. Levent Selamoglu and Kiren Naidoo. The company has several

decades of industry experience across Europe, Middle East and Africa ("EMEA").

The group is well-known for its capabilities across oral solids, injectables

and topical pharmaceutical forms, API production and experience as a contract

manufacturer for a range of multinationals.

The Baystone Group comprises U.K. and U.S.-based specialist pharma investors

closely associated with the growth of SICOR, Inc. and of the IVAX Corp, two

industry-leading specialty pharmaceutical companies with advanced capabilities

across injectables and respiratory technologies, amongst others. The Group is a

major shareholder in Flynn Pharma (comprising operations across the U.K.,

Ireland and Germany) and has a portfolio of pharmaceutical investments spanning

biotechnology and advanced drug delivery.

Source: Frontier Pharma